Projects per year
Organisation profile
Organisation profile
Qatar Biomedical Research Institute (QBRI) is a leading research institute under Hamad Bin Khalifa University (HBKU). The institute addresses the Qatar National Health priorities outlined in the Qatar National Research Strategy through its dedicated research centers – the Translational Oncology Research Center, Diabetes Research Center (DRC) and Neurological Disorders Research Center (NDRC).
Our Vision
QBRI, a national center of excellence and a global hub for biomedical and translational research, aims to improve and transform healthcare through innovation in prevention, diagnosis, and treatment of diseases affecting local and regional populations.
Our Mission
QBRI is engaged in basic and applied medical research that strongly supports the translation of novel scientific discoveries into more efficient therapies and better preventative strategies for human diseases, ultimately leading to the development of personalized medicine.
QBRI Overview
QBRI was founded in 2012 as a national center of excellence and a global hub for biomedical and translational research. The institute works to improve and transform healthcare in Qatar through discoveries in the prevention, diagnosis, and treatment of diseases, affecting the people of Qatar and populations across the region.
QBRI works toward the development of novel biomarkers, and diagnostic and therapeutic solutions to facilitate early diagnosis, treatment, and management of select diseases and improve personalized medicine and healthcare
As a global hub for biomedical and translational research, QBRI continually partners with renowned national and international institutions, enabling the institute to transcend geographical borders and challenges. Above all, QBRI is dedicated to making meaningful contributions to the biomedical field by attracting outstanding scientists, who conduct research in state-of-the-art laboratories featuring a truly unique core technology platform.
The institute is also committed to supporting the next generation of scientists to become highly skilled researchers through mentoring, advanced scientific and research training opportunities and career guidance.
Research Facility
QBRI is located in the 223,000m2 HBKU Research and Development Complex (RDC), which houses unparalleled state-of-the-art research capabilities. The QBRI building is home to three research centers of excellence and seven core facilities. The institute’s renowned facilities house some of the most sophisticated equipment and research apparatus in the Gulf region and worldwide, under one roof.
Inaugurated in 2017, QBRI’s advanced laboratories are major hubs in driving forward cutting-edge research and innovation in Qatar and the region. The facilities are positioned as modern, efficient, reliable and tightly-networked shared resource laboratories to guarantee overarching support and scientific progression on several levels. QBRI’s world-class facilities are actively embedded in a growing national and international collaborative environment, including academic, clinical, and industry partners.
QBRI shares the Research Development Complex with Qatar Computing Research Institute (QCRI) and Qatar Energy and Environment Research Institute (QEERI). The strategically placed shared location creates a unique and combined infrastructure that is specifically designed to comprehensively address the Grand Challenges identified in Qatar National Research Strategy. The proximity facilitates interdisciplinary interaction and the cross-fertilization of ideas in primary research areas.
Fingerprint
Dive into the research topics where Qatar Biomedical Research Institute is active. These topic labels come from the works of this organisation's members. Together they form a unique fingerprint.
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
Profiles
-
Mrs. Eman Suleiman M Abu-Azab
- Qatar Biomedical Research Institute - Research Associate
Person: Employee
-
EX-QNRF-ARG-131: From multi-omics to precision oncology and biological understanding of triple negative breast cancer
Abdesselem, H. B. (Principal Investigator), Ouararhni, K. (Principal Investigator), Al Ejeh, F. H. S. (Lead Principal Investigator), Jeya, S. S. P. (Post Doctoral Fellow) & Mestiri, S. (Research Associate)
15/04/25 → 15/04/28
Project: Experimental Development/Translation Research
-
EX-QNRF-ARG-49: Characterization of all SARS-CoV-2 Mpro & PLpro protease cleavage sites and variants for identifying lead dual protease inhibitor compounds using novel dual color, BRET-based biosensors
Kolatkar, P. R. (Principal Investigator), Aouida, M. (Principal Investigator), Islam, Z. (Post Doctoral Fellow), Biswas, K. H. (Lead Principal Investigator), Geethakumari, A. M. (Post Doctoral Fellow), Khatib, H. A. (Principal Investigator) & Sultana, A. (Research Assistant)
1/04/24 → 1/04/27
Project: Basic Research
-
EX-QNRF-ARG-34: Functional characterization and pharmacological targeting of calcium signaling pathways for the treatment of autism spectrum disorders
Al Haj Zen, A. (Principal Investigator), Park, Y. (Lead Principal Investigator), Da'as, S. (Principal Investigator) & Ali Bakht Jamal, G. (Post Doctoral Fellow)
1/04/24 → 1/04/27
Project: Experimental Development/Translation Research
Research output
-
A Personalized 14-3-3 Disease-Targeting Workflow Yields Repositioning Drug Candidates
Larasati, Y. A., Solis, G. P., Koval, A., Korff, C. & Katanaev, V. L., Apr 2025, In: Cells. 14, 8, 559.Research output: Contribution to journal › Article › peer-review
-
A reciprocal relationship between markers of genomic DNA damage and alpha-synuclein pathology in dementia with Lewy bodies
Koss, D. J., Todd, O., Menon, H., Anderson, Z., Yang, T., Findlay, L., Graham, B., Palmowski, P., Porter, A., Morrice, N., Walker, L., Attems, J., Ghanem, S. S., El-Agnaf, O., LeBeau, F. E. N., Erskine, D. & Outeiro, T. F., 20 Mar 2025, In: Molecular Neurodegeneration. 20, 1, 34.Research output: Contribution to journal › Article › peer-review
-
Ca2+/calmodulin and protein kinase C (PKC) reverse the vesicle fusion arrest by unmasking PIP2
Moussa, H. Y. A., Shin, K. C. & Park, Y., 28 Feb 2025, In: Science advances. 11, 9, eadr9859.Research output: Contribution to journal › Article › peer-review